With organic growth of 13% in the first three months of financial year 2011/12 Chr. Hansen continues its profitable journey.
“Our financial year 2011/12 has started positively. Organic revenue growth reached 13% and with EBIT up by 20% reaching an EBIT margin two percentage points higher than Q1 last year we continue to demonstrate the scalability of our business model. At the same time we have increased our investment in Research & Development which shows our commitment to building a strong future for Chr. Hansen.
In a challenging world economy it is encouraging to see the strength of our growth platform with solid improvements across our regions and divisions. With the strong performance in Q1 we reiterate our outlook for the year," says CEO Lars Frederiksen.
• Revenue EUR 168 million, up 12% compared to Q1 2010/11
• Organic revenue growth of 13%
• EBIT before special items (b.s.i.) EUR 41 million, up 20% compared to Q1 2010/11. EBIT margin before special items 25% compared to 23% in Q1 last year
• The outlook for 2011/12 remains unchanged: Organic growth is expected to be in the range of 7-10% (Excluding effect on sales prices from change in raw material prices for carmine) and EBIT margin b.s.i. is expected to be above 26%
Please see the quarterly report for further details.
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.